Millennium group discloses 4.2% Phathom (PHAT) stake in amended ownership filing

Rhea-AI Filing Summary

Phathom Pharmaceuticals, Inc. received an updated ownership report from Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander. The filers report beneficial ownership of 3,375,834 shares of Phathom common stock, representing 4.2% of the class. They report 0 shares with sole voting or dispositive power and 3,375,834 shares with shared voting and shared dispositive power. The filing indicates that the group now holds 5 percent or less of the outstanding common stock. A joint filing agreement dated July 17, 2026 governs this combined reporting.

Key Figures

Shares beneficially owned: 3,375,834 shares Percent of class: 4.2% Sole voting power: 0 shares +3 more

6 metrics

Shares beneficially owned 3,375,834 shares Beneficially owned by Millennium entities and Israel A. Englander

Percent of class 4.2% Percentage of Phathom common stock beneficially owned

Sole voting power 0 shares Shares with sole power to vote or direct the vote

Shared voting power 3,375,834 shares Shares with shared power to vote or direct the vote

Sole dispositive power 0 shares Shares with sole power to dispose or direct disposition

Shared dispositive power 3,375,834 shares Shares with shared power to dispose or direct disposition

Key Terms

beneficially owned, shared voting power, shared dispositive power, Schedule 13G/A, +1 more

5 terms

beneficially owned financial

"Amount beneficially owned: See response to Item 9 on each cover page."

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared voting power financial

"Shared Voting Power 3,375,834.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power financial

"Shared Dispositive Power 3,375,834.00"

Schedule 13G/A regulatory

""form_type": "SCHEDULE 13G/A""

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Joint Filing Agreement regulatory

"Exhibit I: Joint Filing Agreement, dated as of July 17, 2026"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/20/2026 - 05:53 PM Accepted by SEC EDGAR 07/20/2026 - 05:52 PM Learn about SEC filing dates

FAQ

What ownership stake in PHAT does Millennium Management report in this Schedule 13G/A?

Millennium and related filers report beneficial ownership of 3,375,834 shares of Phathom Pharmaceuticals common stock, representing 4.2% of the outstanding class, with all voting and dispositive power reported on a shared basis.

Who are the reporting persons in the Phathom Pharmaceuticals (PHAT) Schedule 13G/A filing?

The reporting persons are Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, who collectively report beneficial ownership and shared voting and dispositive power over 3,375,834 Phathom common shares.

What percentage of Phathom Pharmaceuticals (PHAT) stock is reported as beneficially owned?

The filing states that the reporting persons beneficially own 4.2% of Phathom Pharmaceuticals’ common stock, corresponding to 3,375,834 shares, with no sole voting or dispositive power and all such powers held on a shared basis.

Does the Millennium group report owning more than 5% of Phathom Pharmaceuticals (PHAT)?

No. Under Item 5, the reporting persons indicate ownership of 5 percent or less of Phathom’s common stock, while specifically disclosing beneficial ownership of 4.2% or 3,375,834 shares with shared voting and dispositive power.

How is voting and dispositive power over PHAT shares allocated for the reporting group?

Each reporting person shows 0 shares with sole voting and sole dispositive power, and 3,375,834 shares with shared voting and shared dispositive power, reflecting control exercised through entities managed by Millennium Management and related parties.

What agreement governs the joint Schedule 13G/A filing for Phathom Pharmaceuticals (PHAT)?

The filing references a Joint Filing Agreement dated July 17, 2026 among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander, under which they file the Schedule 13G/A together regarding their Phathom holdings.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Phathom Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

71722W107

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 71722W107

1

Names of Reporting Persons

Millennium Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,375,834.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,375,834.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,375,834.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.2 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 71722W107

1

Names of Reporting Persons

Millennium Group Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,375,834.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,375,834.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,375,834.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.2 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 71722W107

1

Names of Reporting Persons

Israel A. Englander

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,375,834.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,375,834.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,375,834.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.2 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Phathom Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 100 Campus Drive, Suite 102, Florham Park, New Jersey 07932
Item 2.
(a)	Name of person filing: Millennium Management LLC Millennium Group Management LLC Israel A. Englander
(b)	Address or principal business office or, if none, residence: Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
(c)	Citizenship: Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 71722W107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See response to Item 9 on each cover page.
(b)	Percent of class: See response to Item 11 on each cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See response to Item 5 on each cover page.
	(ii) Shared power to vote or to direct the vote: See response to Item 6 on each cover page.
	(iii) Sole power to dispose or to direct the disposition of: See response to Item 7 on each cover page.
	(iv) Shared power to dispose or to direct the disposition of: See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Millennium Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	07/17/2026

Millennium Group Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	07/17/2026

Israel A. Englander

Signature:	/s/ Israel A. Englander
Name/Title:	Israel A. Englander
Date:	07/17/2026

Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of July 17, 2026, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.